Breaking Q2 Financial Results: Gentherm and Esperion Beat Expectations
- August 01st, 2023
- 421 views
Gentherm Incorporated (Nasdaq: THRM) reported strong second quarter 2023 adjusted earnings per share (EPS) of $0.58, surpassing the consensus estimate of $0.52, and revenues of $372.30 million, beating the analysts' expectation of $368.63 million.
The company reaffirmed its full-year 2023 guidance, expecting product revenues between $1.45 billion and $1.55 billion, against a consensus estimate of $1.51 billion for the period.
In pre-market, $THRM was trading at $60.38, reflecting a gain of $0.61 (+1.02%).
In other news, Esperion Therapeutics, Inc. (Nasdaq: ESPR) delivered better-than-expected financial results.
The company reported a Q2 2023 loss of $0.46 per share, outperforming the consensus estimate of a loss of $0.61 per share, and revenues of $25.79 million, surpassing the analysts' forecast of $24.64 million for the period.
In pre-market trading, $ESPR was at $1.70, showing a gain of $0.13 (+8.28%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026
Member Login